Welcome to our dedicated page for Regenxbio news (Ticker: RGNX), a resource for investors and traders seeking the latest updates and insights on Regenxbio stock.
REGENXBIO Inc. reports news on its AAV gene therapy pipeline and manufacturing platform for rare, neuromuscular and retinal diseases. Recurring updates cover RGX-202 for Duchenne muscular dystrophy; clemidsogene lanparvovec (RGX-121) for MPS II; RGX-111 for MPS I; and surabgene lomparvovec (ABBV-RGX-314) for wet AMD and diabetic retinopathy.
Company announcements also include FDA regulatory communications, clinical and preclinical data presentations, financial results, operational highlights, and collaboration activity with partners including Nippon Shinyaku and AbbVie. News on the NAV and NAVXpress platforms addresses AAV vector technology, product quality, and manufacturing capabilities used across REGENXBIO's investigational programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
REGENXBIO Inc. (Nasdaq: RGNX) will host a conference call on May 3, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ending March 31, 2023, along with recent operational highlights. Participants can register for the webcast through the provided links. The company is known for its NAV Technology Platform, which includes over 100 novel AAV vectors and is utilized in developing a variety of therapeutic programs. REGENXBIO aims to achieve its "5x'25" strategy, which targets advancing five AAV therapeutics into pivotal or commercial stages by 2025.